Papers by Romanian Journal of Oncology and Hematology
Romanian Journal of Oncology and Hematology, Mar 2014
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology and Hematology, Mar 2014
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology and Hematology, Mar 2014
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology and Hematology, Mar 2014
Dasatinib (Sprycel) is a potent Breakpoint Cluster Region-Abelson
(BCR-ABL) oral tyrosine kinase... more Dasatinib (Sprycel) is a potent Breakpoint Cluster Region-Abelson
(BCR-ABL) oral tyrosine kinase inhibitor which has been used in
the treatment of Philadelphia-positive hematological malignancies
such as Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic
Leukemia (ALL). Herein, we describe a case in which the continuous
administration of Dasatinib led, after two months, to the transient
appearance of a clonal, Natural-Killer (NK)-like T-cell population.
This was first detected by the presence of an increased white blood
cell count consisting of lymphocytes, and review of the peripheral
smear showed large granular lymphocytes. The lymphocytosis and
the associated leukocytosis resolved within three weeks without
any interventions while the patient continued Dasatinib. This paper
will review the current literature on this subject, which suggests
that Dasatinib-associated large granular lymphocytosis (LGL) is
associated with a superior disease response.
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology and Hematology, Dec 1, 2013
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma... more B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, known as being part of “grey zone lymphoma” category, displays clinical and biological characteristics which overlap between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. The rarity of these cases represents an extraordinary challenge for both pathologists and hematologists, because the differential diagnosis has direct inferences for the therapeutic strategies. In this paper we present the case of a 29 year old young man diagnosed in April 2010 with classical Hodgkin lymphoma, histologic subtype lymphocyte depletion, that followed 6 cycles chemotherapy (ABVD– Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) without getting an adequate response after salvage chemotherapy (DHAP - Dexamethasone, high-dose Cytarabine, Cisplatin, IGEV - Ifosfamide, Gemcitabine, Vinorelbine) and radiotherapy after which the progressive disease was diagnosed. Reassessment of the lymph node biopsy has led to the diagnosis of unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma, and after immunochemotherapeutic treatment (R-EPOCH - Rituximab, Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, Prednisolone), partial remission was achieved, which has been consolidated by an autologous stem cell transplant which resulted in a complete remission.
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
"For patients with stage I–II Non Small Cells Lung Cancer (NSCLC )
lobectomy remains the standar... more "For patients with stage I–II Non Small Cells Lung Cancer (NSCLC )
lobectomy remains the standard treatment with 5-year survival rates of about 60–80% for stage I and 40–50% for stage II . For medically inoperable patients (or who decline surgery), with good general medical condition that justifies aggressive local treatment and early localised T1-T2 NoMo NSCLC , the Stereotactic Body Radiation Therapy (SB RT) represents a validated therapeutic option. The SB RT deliver a very high dose per fraction (5 Gy to 34 Gy per fraction) in 1 to 5 total fractions. The minimum Biologically Effective Dose, calculated according to the Linear Quadratic (LQ) model with an α/β value of 10, needed to achieve a local control rate of more than 90%, is 100 Gy. To provide highly accurate, precise, and focused radiation delivery, SBRT requires correct patient immobilization, accurate tumour identification and control of the tumour motion. The radiotherapy regimen choice depends on the tumor localization, central versus peripheral, up to 1 cm or more than 1 cm from the chest wall for peripheral tumours and respectively tumor size. The main critical organs at risk that must be delineated are the spinal cord, oesophagus, heart, chest wall and, for apical tumors, the brachial plexus. Regardless of the technique used, when the biological effective dose (BED ) is >100 Gy, the local control rate is 88-96%. The estimated 3-year primary tumour control rate is more than 90% and the survival probability is 70% at 2 years and more than 55% at 3-years and the most important Grade 3 toxicities are pulmonary (dyspnoea and pneumonitis) and chest pain for peripheral tumours. In conclusion, SB RT is superior to conventionally fractionated radiotherapy and today is the standard of care for medically inoperable and early-localised lung cancer patients."
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
"Testicular cancer is relatively rare, but is the most common cancer in males between the ages of... more "Testicular cancer is relatively rare, but is the most common cancer in males between the ages of 15 and 34. Testicular cancer is highly treatable, even when the cancer has spread beyond the testicle. If it is identified early, the chance for successful treatment of testicular cancer is highest. We will discuss in this article the main diagnostic means and treatment indications taking into account the stage and the prognostic factors of disease. Sonoelastography is a new procedure which could
help for diagnostic of disease. The first treatment is surgery (testicular ablation) followed by retroperitoneal lymph node dissection. If lymph nodes are involved, radiotherapy and chemotherapy are indicated. The most indicated combination
of chemotherapy is BEP (Bleomicin, Etoposid and Cisplatin). The number of cycles of chemotherapy varies due to the histological type of tumor (seminoma or nonseminoma), the risk factors represented by tumor TNM stage and tumor markers levels. For the resistant disease, after first line chemotherapy, a combination of Vinblastine, Iphosphamide and Cisplatin is recommended. For metastatic disease which is resistant to first/second line of chemotherapy or relapsed disease we could use GE NOX chemotherapy (Gemcitabine plus oxaliplatin). The actual management of testicular cancer may lead to a better overall survival then in other localizations of cancer."
Bookmarks Related papers MentionsView impact
Romanian Journal of Oncology & Hematology, Dec 1, 2013
"Pain in cancer may be caused by tumour infiltration of pain sensitive
structures or by the trea... more "Pain in cancer may be caused by tumour infiltration of pain sensitive
structures or by the treatment which injures visceral, musculoskeletal, and nervous tissues. Surgery, chemotherapy, and radiation therapy, which are necessary to treat cancer are all associated with potentially painful sequelae. Visceral cancer pain results from infiltration, compression, distension, or stretching of thoracic, abdominal and pelvis viscera. This type of pain is poorly localized and is often referred to cutaneous sites which may be
remote from the site of the lesion. I will talk about this specific physiological type of cancer pain, neurobiological mechanism of nociception, modulation, acute and chronic visceral pain, the locations of the primary tumour and where is the referred pain."
Bookmarks Related papers MentionsView impact
Uploads
Papers by Romanian Journal of Oncology and Hematology
(BCR-ABL) oral tyrosine kinase inhibitor which has been used in
the treatment of Philadelphia-positive hematological malignancies
such as Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic
Leukemia (ALL). Herein, we describe a case in which the continuous
administration of Dasatinib led, after two months, to the transient
appearance of a clonal, Natural-Killer (NK)-like T-cell population.
This was first detected by the presence of an increased white blood
cell count consisting of lymphocytes, and review of the peripheral
smear showed large granular lymphocytes. The lymphocytosis and
the associated leukocytosis resolved within three weeks without
any interventions while the patient continued Dasatinib. This paper
will review the current literature on this subject, which suggests
that Dasatinib-associated large granular lymphocytosis (LGL) is
associated with a superior disease response.
lobectomy remains the standard treatment with 5-year survival rates of about 60–80% for stage I and 40–50% for stage II . For medically inoperable patients (or who decline surgery), with good general medical condition that justifies aggressive local treatment and early localised T1-T2 NoMo NSCLC , the Stereotactic Body Radiation Therapy (SB RT) represents a validated therapeutic option. The SB RT deliver a very high dose per fraction (5 Gy to 34 Gy per fraction) in 1 to 5 total fractions. The minimum Biologically Effective Dose, calculated according to the Linear Quadratic (LQ) model with an α/β value of 10, needed to achieve a local control rate of more than 90%, is 100 Gy. To provide highly accurate, precise, and focused radiation delivery, SBRT requires correct patient immobilization, accurate tumour identification and control of the tumour motion. The radiotherapy regimen choice depends on the tumor localization, central versus peripheral, up to 1 cm or more than 1 cm from the chest wall for peripheral tumours and respectively tumor size. The main critical organs at risk that must be delineated are the spinal cord, oesophagus, heart, chest wall and, for apical tumors, the brachial plexus. Regardless of the technique used, when the biological effective dose (BED ) is >100 Gy, the local control rate is 88-96%. The estimated 3-year primary tumour control rate is more than 90% and the survival probability is 70% at 2 years and more than 55% at 3-years and the most important Grade 3 toxicities are pulmonary (dyspnoea and pneumonitis) and chest pain for peripheral tumours. In conclusion, SB RT is superior to conventionally fractionated radiotherapy and today is the standard of care for medically inoperable and early-localised lung cancer patients."
help for diagnostic of disease. The first treatment is surgery (testicular ablation) followed by retroperitoneal lymph node dissection. If lymph nodes are involved, radiotherapy and chemotherapy are indicated. The most indicated combination
of chemotherapy is BEP (Bleomicin, Etoposid and Cisplatin). The number of cycles of chemotherapy varies due to the histological type of tumor (seminoma or nonseminoma), the risk factors represented by tumor TNM stage and tumor markers levels. For the resistant disease, after first line chemotherapy, a combination of Vinblastine, Iphosphamide and Cisplatin is recommended. For metastatic disease which is resistant to first/second line of chemotherapy or relapsed disease we could use GE NOX chemotherapy (Gemcitabine plus oxaliplatin). The actual management of testicular cancer may lead to a better overall survival then in other localizations of cancer."
structures or by the treatment which injures visceral, musculoskeletal, and nervous tissues. Surgery, chemotherapy, and radiation therapy, which are necessary to treat cancer are all associated with potentially painful sequelae. Visceral cancer pain results from infiltration, compression, distension, or stretching of thoracic, abdominal and pelvis viscera. This type of pain is poorly localized and is often referred to cutaneous sites which may be
remote from the site of the lesion. I will talk about this specific physiological type of cancer pain, neurobiological mechanism of nociception, modulation, acute and chronic visceral pain, the locations of the primary tumour and where is the referred pain."
(BCR-ABL) oral tyrosine kinase inhibitor which has been used in
the treatment of Philadelphia-positive hematological malignancies
such as Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic
Leukemia (ALL). Herein, we describe a case in which the continuous
administration of Dasatinib led, after two months, to the transient
appearance of a clonal, Natural-Killer (NK)-like T-cell population.
This was first detected by the presence of an increased white blood
cell count consisting of lymphocytes, and review of the peripheral
smear showed large granular lymphocytes. The lymphocytosis and
the associated leukocytosis resolved within three weeks without
any interventions while the patient continued Dasatinib. This paper
will review the current literature on this subject, which suggests
that Dasatinib-associated large granular lymphocytosis (LGL) is
associated with a superior disease response.
lobectomy remains the standard treatment with 5-year survival rates of about 60–80% for stage I and 40–50% for stage II . For medically inoperable patients (or who decline surgery), with good general medical condition that justifies aggressive local treatment and early localised T1-T2 NoMo NSCLC , the Stereotactic Body Radiation Therapy (SB RT) represents a validated therapeutic option. The SB RT deliver a very high dose per fraction (5 Gy to 34 Gy per fraction) in 1 to 5 total fractions. The minimum Biologically Effective Dose, calculated according to the Linear Quadratic (LQ) model with an α/β value of 10, needed to achieve a local control rate of more than 90%, is 100 Gy. To provide highly accurate, precise, and focused radiation delivery, SBRT requires correct patient immobilization, accurate tumour identification and control of the tumour motion. The radiotherapy regimen choice depends on the tumor localization, central versus peripheral, up to 1 cm or more than 1 cm from the chest wall for peripheral tumours and respectively tumor size. The main critical organs at risk that must be delineated are the spinal cord, oesophagus, heart, chest wall and, for apical tumors, the brachial plexus. Regardless of the technique used, when the biological effective dose (BED ) is >100 Gy, the local control rate is 88-96%. The estimated 3-year primary tumour control rate is more than 90% and the survival probability is 70% at 2 years and more than 55% at 3-years and the most important Grade 3 toxicities are pulmonary (dyspnoea and pneumonitis) and chest pain for peripheral tumours. In conclusion, SB RT is superior to conventionally fractionated radiotherapy and today is the standard of care for medically inoperable and early-localised lung cancer patients."
help for diagnostic of disease. The first treatment is surgery (testicular ablation) followed by retroperitoneal lymph node dissection. If lymph nodes are involved, radiotherapy and chemotherapy are indicated. The most indicated combination
of chemotherapy is BEP (Bleomicin, Etoposid and Cisplatin). The number of cycles of chemotherapy varies due to the histological type of tumor (seminoma or nonseminoma), the risk factors represented by tumor TNM stage and tumor markers levels. For the resistant disease, after first line chemotherapy, a combination of Vinblastine, Iphosphamide and Cisplatin is recommended. For metastatic disease which is resistant to first/second line of chemotherapy or relapsed disease we could use GE NOX chemotherapy (Gemcitabine plus oxaliplatin). The actual management of testicular cancer may lead to a better overall survival then in other localizations of cancer."
structures or by the treatment which injures visceral, musculoskeletal, and nervous tissues. Surgery, chemotherapy, and radiation therapy, which are necessary to treat cancer are all associated with potentially painful sequelae. Visceral cancer pain results from infiltration, compression, distension, or stretching of thoracic, abdominal and pelvis viscera. This type of pain is poorly localized and is often referred to cutaneous sites which may be
remote from the site of the lesion. I will talk about this specific physiological type of cancer pain, neurobiological mechanism of nociception, modulation, acute and chronic visceral pain, the locations of the primary tumour and where is the referred pain."